GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Bioequivalence Study of Nimesulide 100 mg Tablets
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT01745614
SB-659032 Platelet Aggregation Study
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2012-12-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT01745458
- Locations
- 🇦🇺
GSK Investigational Site, Randwick, Sydney, New South Wales, Australia
To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers
Phase 1
Completed
- Conditions
- Alcoholism
- Interventions
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 56
- Registration Number
- NCT01738867
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
Bioequivalence Study of 300 mg Gabapentin
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT01738893
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults
Phase 3
Completed
- Conditions
- Acellular PertussisTetanusDiphtheria
- Interventions
- Biological: Boostrix
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 165
- Registration Number
- NCT01738477
- Locations
- 🇺🇸
GSK Investigational Site, South Jordan, Utah, United States
A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors
Phase 1
Completed
- Conditions
- Cancer
- Interventions
- Drug: GSK2118436 75 mgDrug: Placebo
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT01738451
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines
Withdrawn
- Conditions
- MumpsRubellaMeaslesVaricella
- Interventions
- Biological: Priorix-Tetra™Other: Safety data collection
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01738841
A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-11-27
- Last Posted Date
- 2016-09-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 494
- Registration Number
- NCT01733758
- Locations
- 🇯🇵
GSK Investigational Site, Yamaguchi, Japan
Study to Assess the Impact of Vaccination on Hospitalizations and Outpatient Visits Due to Rotavirus Gastroenteritis
Completed
- Conditions
- Rotavirus VaccinesInfections, Rotavirus
- Interventions
- Other: Data collection
- First Posted Date
- 2012-11-27
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 5394
- Registration Number
- NCT01733862
- Locations
- 🇯🇵
GSK Investigational Site, Aichi, Japan
A Study to Estimate the Occurrence of Rotavirus Gastroenteritis in Children < 5 Years of Age, in Bulgaria and Latvia
Completed
- Conditions
- Infections, Rotavirus
- Interventions
- Other: Stool sampleOther: Data collection
- First Posted Date
- 2012-11-27
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1266
- Registration Number
- NCT01733849
- Locations
- 🇱🇻
GSK Investigational Site, Ventspils, Latvia
© Copyright 2025. All Rights Reserved by MedPath